AU Patent

AU2020275272A1 — Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors

Assigned to Janssen Biotech Inc · Expires 2021-12-02 · 4y expired

What this patent protects

The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3

USPTO Abstract

The present invention relates to combination therapies with bispecific anti-EGFR/c-Met antibodies and 3

Drugs covered by this patent

lazertinib-mesylate (LAZERTINIB MESYLATE)

Patent Metadata

Patent number: AU2020275272A1
Jurisdiction: AU
Classification: —
Expires: 2021-12-02
Drug substance claim: No
Drug product claim: No
Assignee: Janssen Biotech Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.